1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021 Feb 4, [Online ahead of print].
|
2. |
杨连粤. 孤立性大肝癌的外科治疗进展. 中华外科杂志, 2020, 58(1): 13-16.
|
3. |
王兵, 阎立凯. 腹腔镜下解剖性肝切除术对原发性肝癌的疗效及对相关血清学指标和预后的影响. 肝脏, 2019, 24(3): 283-285.
|
4. |
庄盛威, 林燕燕. 不同肝血流阻断方法对外科手术切除原发性大肝癌患者疗效的影响. 中国现代医生, 2018, 56(29): 38-40.
|
5. |
宋祥勇, 张军, 张永川. 腹腔镜肝切除术与开腹肝切除术治疗原发性大肝癌近期疗效及远期预后对比分析. 解放军预防医学杂志, 2018, 36(4): 451-454.
|
6. |
Duggan MA, Anderson WF, Altekruse S, et al. The Surveillance, Epidemiology, and End Results (SEER) program and pathology: toward strengthening the critical relationship. Am J Surg Pathol, 2016, 40(12): e94-e102.
|
7. |
Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol, 2008, 26(8): 1364-1370.
|
8. |
Kattan MW, Scardino PT. Evidence for the usefulness of nomograms. Nat Clin Pract Urol, 2007, 4(12): 638-639.
|
9. |
Fakhry C, Zhang Q, Nguyen-Tân PF, et al. Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer. J Clin Oncol, 2017, 35(36): 4057-4065.
|
10. |
Lee CK, Goldstein D, Gibbs E, et al. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. Eur J Cancer, 2015, 51(7): 852-860.
|
11. |
Ganly I, Amit M, Kou L, et al. Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study. Eur J Cancer, 2015, 51(18): 2768-2776.
|
12. |
Mitra AP, Lam LL, Ghadessi M, et al. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. J Natl Cancer Inst, 2014, 106(11): dju290.
|
13. |
Kao WY, Su CW, Chiou YY, et al. Hepatocellular carcinoma: nomograms based on the albumin-bilirubin grade to assess the outcomes of radiofrequency ablation. Radiology, 2017, 285(2): 670-680.
|
14. |
Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg, 2015, 261(5): 939-946.
|
15. |
He W, Peng B, Tang Y, et al. Nomogram to predict survival of patients with recurrence of hepatocellular carcinoma after surgery. Clin Gastroenterol Hepatol, 2018, 16(5): 756-764. e10.
|
16. |
Xu L, Peng ZW, Chen MS, et al. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J Hepatol, 2015, 63(1): 122-130.
|
17. |
Kong J, Wang T, Shen S, et al. A nomogram predicting the prognosis of young adult patients diagnosed with hepatocellular carcinoma: A population-based analysis. PLoS One, 2019, 14(7): e0219654.
|
18. |
Benson AB, D’Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2. 2019. J Natl Compr Canc Netw, 2019, 17(4): 302-310.
|
19. |
Hwang S, Lee YJ, Kim KH, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2 558 patients. J Gastrointest Surg, 2015, 19(7): 1281-1290.
|
20. |
Goh BK, Teo JY, Chan CY, et al. Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: Implications on the current AJCC staging system. J Surg Oncol, 2016, 113(1): 89-93.
|
21. |
Subramaniam S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol, 2013, 2(4): 33.
|
22. |
Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int, 2008, 2(1): 17-30.
|
23. |
Liu C, Xiao GQ, Yan LN, et al. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol, 2013, 19(11): 1811-1819.
|
24. |
Di Tommaso L, Sangiovanni A, Borzio M, et al. Advanced precancerous lesions in the liver. Best Pract Res Clin Gastroenterol, 2013, 27(2): 269-284.
|
25. |
Techathuvanan K, Srisajjakul S, Pongpaibul A, et al. Comparison between disease free survival of hepatocellular carcinoma after hepatic resection in chronic hepatitis B patients with or without cirrhosis. J Med Assoc Thai, 2015, 98(4): 334-342.
|
26. |
阎涛, 毕新宇, 方仪, 等. 肝细胞肝癌术后预后因素分析. 实用肿瘤杂志, 2011, 26(4): 337-339.
|
27. |
Vauthey JN, Lauwers GY. Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest? J Hepatol, 2003, 38(2): 237-239.
|
28. |
唐波, 胡志强, 倪斌. 腹腔镜肝切除术与开腹肝切除术治疗原发性大肝癌临床效果的比较研究. 临床合理用药杂志, 2020, 13(3): 142-143.
|
29. |
中国抗癌协会肝癌专业委员会. 原发性肝癌的临床诊断与分期标准. 中华肝脏病杂志, 2001, 9(6): 324.
|
30. |
李彩霞, 张扬, 高莉. 原发性肝癌的介入综合治疗及其预后影响因素. 中华肿瘤杂志, 2006, 28(12): 942-945.
|
31. |
徐向贤, 梁定, 李正军, 等. 肝动脉化疗栓塞联合微波消融术治疗大肝癌的近期疗效探析. 医药前沿, 2020, 10(29): 115-116.
|
32. |
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
|
33. |
Shen SL, Fu SJ, Chen B, et al. Preoperative aspartate aminotransferase to platelet ratio is an independent prognostic factor for hepatitis B-induced hepatocellular carcinoma after hepatic resection. Ann Surg Oncol, 2014, 21(12): 3802-3809.
|
34. |
Lu XY, Xi T, Lau WY, et al. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol, 2011, 137(4): 567-575.
|
35. |
Yan B, Bai DS, Zhang C, et al. Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: A retrospective cohort study in the SEER database. Int J Surg, 2020, 80: 94-100.
|